Immunic Statistics
Total Valuation
Immunic has a market cap or net worth of $177.76 million. The enterprise value is -$8.72 million.
Important Dates
The last earnings date was Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunic has 13.62 million shares outstanding. The number of shares has increased by 103.28% in one year.
| Current Share Class | 13.62M |
| Shares Outstanding | 13.62M |
| Shares Change (YoY) | +103.28% |
| Shares Change (QoQ) | +55.09% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 47.44% |
| Float | 11.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.92, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.92 |
| Quick Ratio | 4.86 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -142.91% and return on invested capital (ROIC) is -93.19%.
| Return on Equity (ROE) | -142.91% |
| Return on Assets (ROA) | -65.18% |
| Return on Invested Capital (ROIC) | -93.19% |
| Return on Capital Employed (ROCE) | -72.43% |
| Weighted Average Cost of Capital (WACC) | 10.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.13M |
| Employee Count | 92 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.85% in the last 52 weeks. The beta is 1.21, so Immunic's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | +41.85% |
| 50-Day Moving Average | 11.27 |
| 200-Day Moving Average | 8.78 |
| Relative Strength Index (RSI) | 62.54 |
| Average Volume (20 Days) | 285,716 |
Short Selling Information
The latest short interest is 1.34 million, so 9.81% of the outstanding shares have been sold short.
| Short Interest | 1.34M |
| Short Previous Month | 8.33M |
| Short % of Shares Out | 9.81% |
| Short % of Float | 11.24% |
| Short Ratio (days to cover) | 4.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -109.64M |
| Pretax Income | -104.29M |
| Net Income | -104.29M |
| EBITDA | -109.48M |
| EBIT | -109.64M |
| Earnings Per Share (EPS) | -$5.07 |
Full Income StatementBalance Sheet
The company has $186.63 million in cash and $146,000 in debt, with a net cash position of $186.48 million or $13.69 per share.
| Cash & Cash Equivalents | 186.63M |
| Total Debt | 146,000 |
| Net Cash | 186.48M |
| Net Cash Per Share | $13.69 |
| Equity (Book Value) | 151.23M |
| Book Value Per Share | 11.10 |
| Working Capital | 150.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.33 million and capital expenditures -$116,000, giving a free cash flow of -$81.45 million.
| Operating Cash Flow | -81.33M |
| Capital Expenditures | -116,000 |
| Depreciation & Amortization | 158,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -81.45M |
| FCF Per Share | -$5.98 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -103.28% |
| Shareholder Yield | -103.28% |
| Earnings Yield | -58.67% |
| FCF Yield | -45.82% |
Analyst Forecast
The average price target for Immunic is $44.67, which is 242.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $44.67 |
| Price Target Difference | 242.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 27, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
